Thrombomodulin is a cell-surface anticoagulant glycoprotein expressed by vascular endothelial cells and epidermal keratinocytes. Thrombomodulin expression in endothelial cells is regulated by retinoic acid and tumor necrosis factora (TNF), agents that also modulate epidermal differentiation. We examined thrombomodulin function and regulation of thrombomodulin expression by all-trans retinoic acid (ATRA) and TNF in human keratinocytes and endothelial cells. Untreated keratinocytes and endothelial cells expressed thrombomodulin of comparable activity and apparent thrombin affinity. Incubation of keratinocytes with 10 pmol/L ATRA for 24 hours increased thrombomodulin activity 5.4 f 0.9-fold (mean 5 SE), with equivalent increases observed in thrombomodulin protein (5.5 f 2.1-fold) and HROMBOMODULIN IS A membrane-bound glycoprotein that functions as an endogenous anticoagulant by altering the substrate specificity of the serine protease thrombin.' When bound to thrombomodulin, thrombin's procoagulant activities are inhibited, and thrombin and thrombomodulin form a catalytic complex that efficiently activates the anticoagulant protein C. Activated protein C enzymatically degrades coagulation factors V, and VIIIa, resulting in decreased thrombin production and inhibition of coagulation.
HROMBOMODULIN IS A membrane-bound glycoprotein that functions as an endogenous anticoagulant by altering the substrate specificity of the serine protease thrombin.' When bound to thrombomodulin, thrombin's procoagulant activities are inhibited, and thrombin and thrombomodulin form a catalytic complex that efficiently activates the anticoagulant protein C. Activated protein C enzymatically degrades coagulation factors V, and VIIIa, resulting in decreased thrombin production and inhibition of coagulation.
Thrombomodulin is expressed on the luminal surface of endothelium and syncitiotrophoblast, where it functions to limit coagulation to sites of vascular injury.' Thrombomodulin is also expressed by several types of nonvascular cells, including mesothelium3 and spinous layer keratinocytes of squamous epitheli~m.~" During embryonic development, thrombomodulin is expressed in both vascular and nonvascular sites, including developing lung bud, heart valves, and neur~epithelium.~.~ Homozygous germline disruption of the thrombomodulin gene in mice results in lethality early in embryonic development." These observations raise the possibility that thrombomodulin may function differently on vascular and nonvascular cells.
Expression of thrombomodulin in cultured endothelial cells is downregulated by inflammatory cytokines such as tumor necrosis factor (TNF) and interleukin-l.""s In contrast, exposure of endothelial cells to retinoic acid results in upregulation of thrombomodulin transcription and in abrogation of the downregulating effects of inflammatory cytokine^.'^.'' Although epidermal differentiation is known to be modulated by TNF and retinoic acid,I8.l9 the effect of these agents on thrombomodulin expression in keratinocytes is unknown.
In human keratinocytes, thrombomodulin expression increases when the concentration of calcium ions in the culture medium is increased from 0.07 mmoVL to l . 4 activation.** However, the effect of [Ca"] on the activity of keratinocyte thrombomodulin has not been determined.
In this study, we measured the thrombin affinity of thrombomodulin in keratinocytes and endothelial cells, and compared the effects of all-trans retinoic acid (ATRA) and TNF on thrombomodulin expression in these cell types. In addition, we determined the [Ca"] dependence of protein C activation by thrombin in the presence of keratinocyte thrombomodulin. The results indicate that keratinocytes and endothelial cells express thrombomodulin with similar apparent thrombin affinity, but that ATRA is a more potent stimulus of thrombomodulin expression in keratinocytes than in endothelial cells. In contrast to ATRA, TNF markedly inhibited thrombomodulin expression in endothelial cells, but not in keratinocytes. The activity profile of keratinocyte thrombomodulin exhibited a distinct maximum near 1.0 mrnol/L Ca'+, a concentration that may support optimal activity in the spinous layer of epidermis.
thrombin 111 were generous gifts of Dr Hans Peter Schwarz (Immuno AG, Vienna, Austria) and Dr Douglas Tollefsen (Washington University, St Louis, MO), respectively. Rabbit lung thrombomodulin was purchased from American Diagnostica, Inc (Greenwich, CT). Recombinant TM456 was purified from tissue culture medium as described previously." Porcine intestinal heparin was obtained from Elkins-Sinn, Inc (Cherry Hill, NJ), and S-2366 was purchased from Kabi Pharmacia Hepar, Inc (Franklin, OH).
Cell culture. Human umbilical vein endothelial cells (HUVEC) and neonatal human foreskin keratinocytes were purchased from Clonetics Corporation (San Diego, CA). All cells were studied within 2 to 4 passages after primary culture. HUVEC were cultured in endothelial growth medium containing 2% fetal bovine serum (FBS) as described previo~sly.~ Keratinocytes were cultured in serum-free keratinocyte growth medium (KGM) containing 0.07 mmol/L calcium chloride. When keratinocyte cultures reached 75% confluency, the medium was changed to KGM containing 1.4 m m o l n calcium chloride, and the cells were cultured for up to 96 hours in the presence of various concentrations of ATRA or TNF. Control cultures were incubated with either 0.1% dimethyl sulfoxide (DMSO; the vehicle for ATRA) or 0.3% phosphate-buffered saline (PBS; the vehicle for TNF).
Protein C activation. Protein C activation was measured using a two-stage assay described previ~usly.~ Cells were washed three times with PBS and lysates were prepared in 20 mmol/L Tris-HCI, pH 8.0,0.6% Triton X-100, and 100 mmol/L NaCI. The total protein concentration of cell lysates was measured by a modified Bradford assay (Bio-Rad Laboratories, Richmond, CA). For measurement of thrombomodulin cofactor activity, lysates were incubated for 30 minutes at 37°C with 2.6 nmol/L human thrombin, 0.84 pmol/L human protein C, and various Concentrations of CaCI,. The reaction was stopped by addition of a mixture of antithrombin 111 (25 pgI mL) and heparin (25 U/mL), and the amidolytic activity of activated protein C was measured with the chromogenic substrate S-2366. All assays were performed in replicate (n = 3 to 6) and statistical comparisons were made using the two-tailed Student's t-test.
For determination of apparent equilibrium dissociation constant the initial rate of protein C activation was measured in the presence of fixed concentrations of protein C (0.84 pnol/L) and CaCl, (2.5 mmol/L), and increasing concentrations of thrombin (0 to 50 nmol/L). &(app) was defined as the concentration of thrombin that produced half-maximal thrombomodulin cofactor activity, as determined by nonlinear regression analysis (Sigmaplot, Jandel Scientific, San Rafael, CA).
Immunoblot analysis. Cells were washed three times with PBS and lysates were prepared in 20 mmoUL Tris-HC1, pH 8.0, 0 . 6 6 Triton X-100, 100 m m o l n NaCl, 3.0 mmol/L CaCI,, and 10 mmol/ L iodoacetamide. After centrifugation at 12,000g for 5 minutes, supernatant fractions containing 50 pg of total protein were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) under nonreducing conditions. Immunoblot analysis was performed as described previously' using mouse antihuman thrombomodulin monoclonal antibody TM1009 (Dako Corp, Carpinteria, CA) or mouse antihuman keratinocyte transglutaminase monoclonal antibody B.C1 (kindly provided by Dr Robert H. Rice, University of California, Davis, CA)24 with enhanced chemiluminescence detection.
Nuclease SI protection analysis. Plasmids containing cDNA inserts for human thrombomodulin (pUC 19TM 12)'' and human y actin (pHFyA-l, provided by Dr L. Kedes, University of Southern California, Los Angeles, CA)" were linearized by digestion with MluI and BglII, respectively. The linearized plasmids were treated with calf intestinal alkaline phosphatase, and end-labeled with [ Y~~P ] A T P and T4 polynucleotide kinase. Total cellular RNA was isolated from cultured cells by acid guanidinium thiocyanate-phenolchloroform extraction (Tri-reagent; Molecular Research, Inc. Cincinnati. OH). The end-labeled thrombomodulin and actin plasmids were hybridized overnight at 55°C with S0 p g or S p g of total cellular RNA. respectively, and analyzed by denaturing gel electrophoresi\ as described previously."
Densitometry. Laser densitometry of nuclease S1 protection autoradiographs and immunoblots was performed using a 300s cornputing densitometer with ImageQuant v5.0 software (Molecular Dynamics, Sunnyvale, CA).
RESULTS
Previous studies have shown that keratinocytes and endothelial cells contain thrombomodulin with similar apparent molecular mass and specific cofactor To determine whether keratinocyte thrombomodulin and endothelial cell thrombomodulin differ in affinity for thrombin, we measured the apparent dissociation constant in a protein C activation assay. In three separate experiments, Kd,+,p, for thrombin ranged from 5.3 2 0.3 to 8.4 t 0.5 nmol/L with keratinocyte thrombomodulin (Fig 1A) and from 3. I t 0.4 nmol/L to 5.6 2 1.3 nmol/L with HUVEC thrombomodulin (Fig IB) . These values, which are similar to those reported for other preparations of human thrombomodulin,2x indicate that thrombin binds to keratinocyte thrombomodulin and endothelial cell thrombomodulin with similar affinity.
Effecn cf ATRA and TNF on tkromhomodulin cojc1ctor activiv. The effect of ATRA on the activity of keratinocyte thrombomodulin was measured in protein C activation assays with lysates prepared from keratinocytes incubated with various concentrations of ATRA for 24 hours (Fig 2A) . ATRA produced a dose-dependent increase in thrombomodulin cofactor activity, with maximum activity after incubation with 20 pmol/L ATRA. Incubation with higher concentrations of ATRA caused cell toxicity. The time course of ATRA-induced increase in thrombomodulin activity is shown in Fig 2B . When keratinocytes were cultured for 96 hours in the presence of 10 ,umol/L ATRA, thrombomodulin cofactor activity peaked at 24 hours, and then declined gradually. As reported previously," a more modest increase in thrombomodulin activity was observed when keratinocytes were incubated with 1.4 mmol/L calcium in the absence of ATRA.
In agreement with previous studies,"." incubation of HU-VEC with 10 pmol/L ATRA for 24 hours produced a small but significant increase in thrombomodulin activity (Fig 3A) . However, the increase in thrombomodulin activity induced by this concentration of ATRA was considerably greater in keratinocytes (5.4 L 0.9-fold) than in HUVEC (1.9 f 0. Ifold). In contrast to ATRA, TNF produced a marked decrease in thrombomodulin activity in HUVEC, but had little effect on thrombomodulin activity in keratinocytes. Incubation of HTJVEC with 1.0 nmoVL TNF for 24 hours decreased thrombomodulin activity by 83% 2 7% (Fig 3B) . In several experiments, incubation of keratinocytes with TNF for up to 5 days resulted in no significant change in thrombomodulin expression compared with control keratinocytes incubated with PBS.
Effects of ATRA und TNF on thrombomodulin protein and mRNA. In endothelial cells, ATRA and TNF regulate thrombomodulin expression primarily at the level of tran- scription, producing equivalent changes in thrombomodulin protein and
To determine effects of ATRA and TNF on thrombomodulin protein and mRNA in keratinocytes, immunoblot and nuclease S1 protection analyses were performed. Similar amounts of thrombomodulin protein (Fig  4) and mRNA (Fig 5) were detected in keratinocytes incubated for 24 hours with 1.0 nmol/L TNF or vehicle (PBS or DMSO). Keratinocytes incubated for 24 hours with 10 pmoV L ATRA contained markedly increased amounts of thrombomodulin protein (Fig 4) and thrombomodulin mRNA ( Fig  5) compared with keratinocytes incubated with TNF, PBS, or DMSO. No treatment-related changes in the level of actin mRNA were observed (Fig 5) . Mean ATRA-induced increases in thrombomodulin protein (5.5 ? 2.1-fold in five experiments) and thrombomodulin mRNA (4.2 +. 1.2-fold in two experiments) were similar in magnitude to increases in thrombomodulin activity observed in ATRA-treated keratinocytes (Fig 3A) .
Although cultured keratinocytes have been reported to express functional TNF receptors,'x the failure of TNF to alter thrombomodulin expression raised the possibility that keratinocytes may lack responsiveness to TNF under these culture conditions. To test this possibility, immunoblot analysis was performed using a monoclonal antibody to keratinocyte transglutaminase, a marker of keratinocyte differentiation that is synthesized in the granular layer of e p i d e~m i s .~~ In agreement with previous we detected increased expression of transglutaminase after keratinocytes were cultured for 3 days in KGM containing 1.4 mmol/L Ca2' and either PBS or DMSO (Fig 6) . The increase in keratinocyte transglutaminase was inhibited by addition of 10 pmol/L ATRA, and enhanced by addition of 1.0 nmol/L TNF, confirming that keratinocytes respond to TNF under these cul-
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In this experiment (Fig 6) , peak induction of thrombomodulin protein was observed 3 days after addition of ATRA (lane 8). In other experiments, peak induction of thrombomodulin was observed at various times between 1 and 3 days after addition of ATRA. More rapid induction of thrombomodulin expression was observed with keratinocyte monolayers that were more than -70% confluent, and slower induction was observed with less confluent cultures. thrombomodulin fragment that comprises the fourth through sixth EGF-like domains of human thrombomodulin.2' Keratinocyte thrombomodulin demonstrated a biphasic activity profile, with activity increasing sharply as the CaC& concentration was increased from 0 to 1.0 mmol/L, and activity decreasing at higher CaC12 concentrations (Fig 7A) . TM456 also produced a biphasic activity profile, with peak activity at a slightly lower CaC12 concentration (0.5 mmol/L) than keratinocyte thrombomodulin (Fig 7B) . Rabbit thrombomodulin exhibited a simple hyperbolic activity profile, with maximal activity at saturating concentrations of calcium ions (Fig 7C) .
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To determine whether stimulation with ATRA altered the calcium-dependence or thrombin affinity of keratinocyte thrombomodulin, keratinocytes were incubated with or without IO pnol/L ATRA for 24 hours, and thrombomodulin activity was measured in the presence of either 1.0 or 4.0 mmoln CaCI2. The ratio of thrombomodulin activities at 1.0 mmol/L and 4.0 mmol/L CaC12 was 2.8 for ATRAtreated keratinocytes, compared with 3.8 for untreated keratinocytes, 7.1 for TM456, and 0.4 for rabbit thrombomodulin. The &(app) for thrombin of thrombomodulin in ATRA-treated keratinocytes was 5.2 ? 1.8 nmoVL, which is similar to that of thrombomodulin in untreated keratinocytes (Fig 1A) .
DISCUSSION
Thrombomodulin was identified 15 years ago as an endothelial cell cofactor for protein C activation." Recent evidence from several laboratories has established that thrombomodulin is expressed not only by vascular endothelial cells, but also by nonvascular cells such as keratin~cytes."~ AIthough the function of thrombomodulin in nonvascular locations is poorly understood, its pattern of expression during embryogenesis suggests a possible role in cellular development and differentiation.'." This possibility is supported by the observation that homozygous deficiency of thrombomodulin produces an embryonic lethal phenotype in mice."
Previous studies have shown that thrombomodulin expression correlates strongly with epidermal differentiation in vivo, and with calcium-induced keratinocyte differentiation in vitro. 4 ." This study demonstrates that keratinocyte thrombomodulin and endothelial cell thrombomodulin have similar cofactor activity and thrombin affinity, but differ in their responses to regulatory stimuli. Unlike thrombomodulin expression in endothelial cells, thrombomodulin expression in keratinocytes was stimulated markedly by ATRA, but was unaffected by TNF. Retinoids regulate epidermal differentiation in a complex manner. Based on in vitro studies, as well as observations in animals with vitamin A deficiency (which produces epithelial changes such as hyperkeratosis and squamous metaplasia of transitional and columnar epithelium), it has been suggested that retinoic acid may inhibit epidermal differentiation.2'J However, recent data from mice with targeted overexpression of dominant-negative retinoic acid receptor genes indicate that retinoids may be necessary for normal epidermal
The observation that ATRA is a potent stimulator of thrombomodulin expression in keratinocytes suggests that retinoids may play a physiological role in the regulation of thrombomodulin expression during squamous differentiation.
Dittman et aIz7 have identified functional retinoic acid response elements within the 5"flanking region of the human thrombomodulin gene. These investigators suggested that the thrombomodulin promoter may be more responsive to retinoids in cells with low basal levels of thrombomodulin expression than in cells with high basal levels of thrombomodulin expression. Our observations in keratinocytes are consistent with transcriptional regulation of the thrombomodulin gene by ATRA, in that increased thrombomodulin activity in ATRA-treated keratinocytes was associated with increased levels of thrombomodulin mRNA. However, despite similar levels of basal thrombomodulin expression, we observed a greater response to ATRA in keratinocytes than in HUVEC. This suggests that responsiveness of the thrombomodulin promoter to retinoic acid is regulated independently of the basal transcription rate.
The failure of TNF to alter expression of keratinocyte thrombomodulin while markedly stimulating expression of keratinocyte transglutaminase also suggests differential responsiveness of the thrombomodulin promoter. Recent studies indicate that an Ets-like element within the proximal thrombomodulin promoter may be involved in TNF-mediated transcriptional inhibition in endothelial ~e l l s .~' .~~ This sequence appears to recognize a novel nuclear factor that is present in endothelial cells." Whether this factor is responsible for TNF-mediated inhibition of thrombomodulin tran-RAIFE, DEMETROULIS, AND LENT2 scription has not been determined, and it is not known if this factor is present in keratinocytes.
Protein C contains a high-affinity CaZ+ site that must be occupied for efficient activation by the thrombidthrombomodulin complex.' The effect of Ca2+ on protein C activation is also influenced by the glycosylation state of thrombomodulin. Isoforms of thrombomodulin that lack chondroitin sulfate (CS) exhibit peak cofactor activity at [Ca"] below 1 .O mmol/L, whereas isoforms containing CS are most active at saturating [Ca"].' Studies with cultured endothelial cells indicate that a variable fraction of human thrombomodulin js devoid of CS,22 implying paradoxically that protein C activation may be suboptimal at plasma [Ca"]. With both untreated and ATRA-treated keratinocytes, we observed maximal thrombomodulin activity at 1.0 mmol/L Ca", which suggests that keratinocyte thrombomodulin does not contain large amounts of CS. However, the possibility that CS may have been lost or modified during preparation of cell lysates cannot be excluded.
Unlike endothelial cell thrombomodulin, keratinocyte thrombomodulin may be exposed to extracellular [Ca"] lower than that found in plasma. In vivo studies in mice suggest that an extracellular [Ca"] gradient exists within the stratified squamous epithelium of the epidermis, with lower [Ca"] in the basal and spinous layers, and higher [Ca"] in the granular layer.*',*' Thrombomodulin is selectively expressed in the spinous layer: where relatively low extracellular [Ca"] may support optimal cofactor activity.
In summary, we have shown that the thrombin affinity and basal level of expression of thrombomodulin are similar in cultured keratinocytes and endothelial cells, but that regulation of thrombomodulin expression differs in these two cell types. Keratinocyte thrombomodulin is upregulated strongly by ATRA, but is unaffected by TNF. In contrast, endothelia1 cell thrombomodulin is upregulated weakly by ATRA, and downregulated strongly by TNF. Therefore, clinical settings associated with the production or administration of retinoids or inflammatory cytokines may produce differential effects on thrombomodulin expression in blood vessels and epidermis. These data provide additional support for the hypothesis that thrombomodulin has distinct biological functions in vascular and nonvascular cells.
